Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

To join this study, you need to be at least 18 years old. You must also be generally well enough to take part, meaning you can look after yourself for most of the day and have good basic organ function. Your cancer needs to be measurable, which means doctors can clearly see and track its size. You should also expect to live for at least 12 weeks.

There are certain reasons why you might not be able to join. For example, if your cancer has spread to your brain in a way that is causing symptoms or needs medication, you might not be eligible for most groups. Also, certain types of cancer or previous medical conditions, like some uncontrolled infections or other serious illnesses, might prevent you from taking part. If you’ve recently had radiotherapy or have allergies to certain chemotherapy drugs used in the study, you might also be excluded from specific groups.

The research team will carefully review your medical history and current health to determine if this study is suitable for you. They will explain everything in detail and answer any questions you have.

If you decide to take part in this study, you will receive the new medicine, Volrustomig. Depending on which group you are in, you might receive Volrustomig on its own or together with standard chemotherapy drugs like Cisplatin, Carboplatin, Paclitaxel, or 5-FU. You will have regular appointments for check-ups, which will include blood tests and scans, to monitor the cancer's response and to look for any side effects. You will need to provide a small sample of your tumour tissue. The exact schedule of visits and treatments will vary depending on your specific study group, but you can expect ongoing monitoring for the duration of your participation in the study. The total duration of your involvement will be explained to you by the study team.